Metabolomics Annotates ABHD3 As a Physiologic Regulator of Medium-Chain Phospholipids

Jonathan Z Long,Justin S Cisar,David Milliken,Sherry Niessen,Chu Wang,Sunia A Trauger,Gary Siuzdak,Benjamin F Cravatt
DOI: https://doi.org/10.1038/nchembio.659
IF: 14.8
2011-01-01
Nature Chemical Biology
Abstract:An untargeted metabolomics approach identifies C14 phosphatidylcholines (PCs) as specific cellular medium-chain substrates of the lipase ABHD3, as well as C5–C8 short-chain PCs including oxidized pro-atherosclerotic and pro-apoptotic PC phospholipids. All organisms, including humans, possess a huge number of uncharacterized enzymes. Here we describe a general cell-based screen for enzyme substrate discovery by untargeted metabolomics and its application to identify the protein α/β-hydrolase domain–containing 3 (ABHD3) as a lipase that selectively cleaves medium-chain and oxidatively truncated phospholipids. Abhd3−/− mice possess elevated myristoyl (C14)-phospholipids, including the bioactive lipid C14-lysophosphatidylcholine, confirming the physiological relevance of our substrate assignments.
What problem does this paper attempt to address?